Isoproterenol enhancement of IKs current in Amiodarone-induced Long QT Syndrome

Raviña, Tomás; Raviña, Manuela; Gutiérrez, Javier

doi:10.1016/j.ijcard.2007.07.175

Cited by 5 publications

(4 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, it has also been hypothesized that isoproterenol increases the generation of signals from the β-adrenergic receptor restoring the components of hKCNQ1 macromolecular complex, thereby shortening the QT interval and normalizing the T-wave morphology. 8 Isoproterenol was also found to shorten the basic cycle length, corrected QT interval, and decreased the dispersion of ventricular refractoriness in quinidineinduced torsades. 9 Low-dose isoproterenol has also been useful in the treatment of ventricular arrhythmias associated with Brugada syndrome.…”

Section: Discussionmentioning

confidence: 95%

“…One possible explanation for the effectiveness of isoproterenol is by increasing the sinus rate that will tend to decrease the absolute QT interval. However, it has also been hypothesized that isoproterenol increases the generation of signals from the β‐adrenergic receptor restoring the components of hKCNQ1 macromolecular complex, thereby shortening the QT interval and normalizing the T‐wave morphology 8 . Isoproterenol was also found to shorten the basic cycle length, corrected QT interval, and decreased the dispersion of ventricular refractoriness in quinidine‐induced torsades 9 .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Fetal and Neonatal Presentation of Long QT Syndrome

Komarlu

Beerman

Freeman

et al. 2011

Pacing Clinical Electrophis

View full text Add to dashboard Cite

This report describes a fetus presenting with intrauterine tachycardia and hydrops fetalis. Soon after birth the neonate was noted to be in torsades de pointes that responded dramatically to medical management. Long QT syndrome (LQTS) was diagnosed on electrocardiogram obtained soon after birth. The prognosis is poor when LQTS presents in utero or during the first week of life. However, our infant did well with medical management and has remained free of arrhythmias at follow-up.

show abstract

Section: Discussionmentioning

confidence: 95%

Section: Discussionmentioning

confidence: 99%

Fetal and Neonatal Presentation of Long QT Syndrome

Komarlu

Beerman

Freeman

et al. 2011

Pacing Clinical Electrophis

View full text Add to dashboard Cite

show abstract

“…Ranolazine, a late INa blocker, was seen to be effective to shorten the QT interval as well as suppress TdP as proved by experimental models of LQT3 [26]. Dose-dependent shortening of QT interval was achieved in human patients with DKPQ mutation of LQT3 using ranolazine [27]. What seems to be a therapeutic paradox is the benefit of adrenergic stimulation in cases with acquired LQTS and low heart rate with pauses.…”

Section: Sudden Cardiac Deathmentioning

confidence: 95%

Inherited Ventricular Arrhythmias, the Channelopathies and SCD: Current Knowledge and Future Speculations - Risk Stratification, Management Plans and Future Speculations

Abdulgader¹

2020

Sudden Cardiac Death

View full text Add to dashboard Cite

Channelopathy constitutes significant proportion of SCD worldwide (around 10% or 370,000 deaths annually). It was creating a mysterious group of diseases until the second half of the last century when Anton Jervell and Fred Lange-Nielsen described Jervell Lange-Nielsen syndrome in 1957. It was late until 1995 where genetic characterization commenced. Later on, the massive genetic information with the discovery of genetic heterogeneity and allelic het¬erogeneity was a major victory in the field. The basic sciences in cellular electrophysiology and genetics complemented by meticulous clinical detection and the different clinical trials in the field opened a new era of wide therapeutic choices for clinicians. The knowledge obtained from the different experimental platforms especially the induced pluripotent stem cells is promising. The revolutionary move in SCD and channelopathies is described where correlation between the arrhythmogenesis and fluctuation in SGMA is established and must be investigated. The observation of the arrhythmogenicity of SGMA fluctuation and its effect on HRV together with the differential effect of certain sympathovagal tones (more sympathetic innervation is favoring VT/VF in LQTS1, LQTS2 and SQTS but not BrS or ERS) are all future directions to optimize our preventive, diagnostic as well as therapeutic options of SCD and channelopathy in humans.

show abstract

“…In 70% -80% of patients with acute coronary syndrome, atropine (1 -3 mg) can be useful for the treatment of symptomatic bradycardia; in fact, intravenous administration of atropine can lead to increased heart rate. However, some elderly patients with bradycardia are resistant to atropine, and therefore, other drugs such as aminophylline (1), isoproterenol (2), and ephedrine (3) are used for the management of symptomatic bradycardia.…”

Section: Introductionmentioning

confidence: 99%

Ephedrine Is More Effective Than Atropine for the Treatment of Symptomatic Bradycardia in Elderly Patients

Shahriari

Khooshideh

2017

Shiraz E-Med J

View full text Add to dashboard Cite

Background: Bradycardia may result in the exacerbation of myocardial dysfunction in elderly patients. Objectives: In this retrospective cohort study, ephedrine and atropine were compared for the treatment of symptomatic bradycardia. Methods: In this study, patients (above 65 years) with symptomatic bradycardia during skin tumor resection were evaluated. Symptomatic bradycardia was defined as heart rate below 49 beats per minute and systolic blood pressure below 85 mmHg. According to the anesthesiologist's decision, 1 group of patients (atropine group) received atropine (0.5 mg) as the first-line drug, while the other group (ephedrine group) received ephedrine (10 mg) as the first-line drug to restore hemodynamic parameters. If the initial treatment had no effects on the management of the symptoms, ephedrine (10 mg) was administered to the patients in both groups. The number of patients, who received treatment with a single drug to normalize their hemodynamic parameters, was compared with those who required a second drug. Results: Among 194 subjects with symptomatic bradycardia, 86 and 108 patients were allocated to the atropine and ephedrine groups, respectively. Based on the findings, 35 patients in the atropine group required the second drug for bradycardia management; therefore, 51 patients were treated with only atropine (efficacy: 51/86, 59.30%). Moreover, 21 patients in the ephedrine group required the second dose of ephedrine for the management of bradycardia; consequently, 87 patients were treated with only ephedrine (efficacy: 87/108, 80.55%). There was a statistically significant difference between the 2 groups (P = 0.001). Conclusions: Ephedrine is more effective than atropine in the management of symptomatic bradycardia in elderly patients.

show abstract

Isoproterenol enhancement of IKs current in Amiodarone-induced Long QT Syndrome

Cited by 5 publications

References 21 publications

Fetal and Neonatal Presentation of Long QT Syndrome

Fetal and Neonatal Presentation of Long QT Syndrome

Inherited Ventricular Arrhythmias, the Channelopathies and SCD: Current Knowledge and Future Speculations - Risk Stratification, Management Plans and Future Speculations

Ephedrine Is More Effective Than Atropine for the Treatment of Symptomatic Bradycardia in Elderly Patients

Contact Info

Product

Resources

About